Abbott Laboratories (ABT) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-02-20
Business type: Franchise
How it makes money
It generates its highest operating margins from Medical Devices, driven by its FreeStyle Libre sensors and structural heart devices like the MitraClip.
Medical Devices delivered a 33.7% operating margin in 2025, significantly outperforming its other reportable segments. This growth is centered on Diabetes Care, where continuous glucose monitoring systems generated $7.6 billion in annual sales.
Profitability is also influenced by sales volume in branded generic pharmaceuticals across emerging markets, where it grew sales by 5.1% in 2025, excluding the impact of foreign exchange.
What protects it: the moat
It leverages its Alinity testing platform and digital health solutions to secure recurring revenue through the continued deployment of its diagnostic test menus.
It defends its diagnostics market share by installing its Alinity platforms under long-term supply contracts that secure recurring test volume in clinical laboratories. This creates technical and contractual inertia for its core laboratory and transfusion medicine systems.
It further integrates its systems into hospital workflows using AlinIQ informatics tools and GLP systems Track to enhance laboratory efficiency.
What growth costs
It is increasing its leverage to fund a $21 billion acquisition of Exact Sciences to enter the cancer diagnostics market.
Beyond recurring research and development, it has committed to approximately $20 billion of borrowings to fund the acquisition of Exact Sciences.
It also faces significant structural costs from sales rebates, which reduced its gross sales by $4.8 billion in 2025, primarily within its Nutritional and Diabetes Care businesses.
What could damage it
Complex manufacturing requirements can lead to total facility shutdowns or product seizures, as seen with its 2022 infant formula recall and consent decree.
Because its products are subject to strict FDA oversight, a failure in protocol at a single site can trigger a voluntary recall or a government-mandated stoppage. For example, a 2022 recall at its Sturgis, Michigan facility resulted in a temporary manufacturing halt and a subsequent consent decree.
Changes in government benefit programs, such as the WIC cost containment rebates for infant formula, also pose a risk of forced price reductions that could impair segment earnings.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.